Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.
There have been some concerns that the immunomodulatory effect of PD-1 blockade may influence the response of patients with cancer to COVID-19.
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
Recent studies have led to important insights regarding the role of viruses in asthma pathogenesis and exacerbations, as well as mediating factors involved in these processes.
Patients with COVID-19 who also have poor baseline health and/or obesity are more likely to demonstrate impaired respiratory muscle performance.
Despite significant advances in asthma treatment in the past decades, the disease is still poorly controlled in an estimated 50% of patients.
Patients with asthma and COPD appear to have increased their adherence to inhaler medications in the wake of the COVID-19 pandemic.
The impact of COVID-19 on the global health system and economy will likely result in large-scale changes in zoonotic disease prevention preparedness.
Mitigating the spread of a virus as infectious as SARS-CoV-2 requires having ample and accurate diagnostic tests available. However, in the United States, community transmission began to occur before adequate testing measures could be implemented.
Progression in characterizing the symptoms and treatments for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent development of coronavirus disease 2019 (COVID-19).